Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease
…, DR De La Blétiere, A Bourreille, V Leray, N Gervois… - Gut, 2000 - gut.bmj.com
BACKGROUND/AIM Proinflammatory cytokines are key factors in the pathogenesis of
Crohn's disease (CD). Activation of nuclear factor kappa B (NFκB), which is involved in their …
Crohn's disease (CD). Activation of nuclear factor kappa B (NFκB), which is involved in their …
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
…, JF Fonteneau, CM Lizana, N Gervois… - The Journal of …, 1998 - journals.aai.org
Abstract The Melan-A/MART-1 gene, which is expressed by normal melanocytes as well as
by most fresh melanoma samples and melanoma cell lines, codes for Ags recognized by …
by most fresh melanoma samples and melanoma cell lines, codes for Ags recognized by …
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
…, L Blanchard, JP Girard, A Jarry, N Gervois… - Science, 2023 - science.org
Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1)
blockade in cancer patients, but the mechanisms underlying their immunosuppressive …
blockade in cancer patients, but the mechanisms underlying their immunosuppressive …
Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment
T Passat, Y Touchefeu, N Gervois, A Jarry… - Bulletin du …, 2018 - europepmc.org
Recently, the emergence of anti-CTLA-4 and anti-PD-1/PD-L1 antibodies called immune
check-point inhibitors (ICPI) has modified the landscape of anti-cancer treatments. These …
check-point inhibitors (ICPI) has modified the landscape of anti-cancer treatments. These …
Inhibition of antigen‐induced T cell response and antibody‐induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP‐1 and SHP‐2 protein‐tyrosine …
…, S Guia, G Krystal, N Gervois… - European journal of …, 1998 - Wiley Online Library
Subsets of T and natural killer (NK) lymphocytes express the CD94‐NKG2A heterodimer, a
receptor for major histocompatibility complex class I molecules. We show here that …
receptor for major histocompatibility complex class I molecules. We show here that …
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells
…, A Moreau-Aubry, F Jotereau, N Gervois - The Journal of …, 2006 - journals.aai.org
Abstract HLA-E are nonclassical MHC molecules with poorly characterized tissue
distribution and functions. Because of their capacity to bind the inhibitory receptor …
distribution and functions. Because of their capacity to bind the inhibitory receptor …
[HTML][HTML] Double positive CD4CD8 αβ T cells: a new tumor-reactive population in human melanomas
…, A Khammari, B Dreno, F Jotereau, N Gervois - PloS one, 2010 - journals.plos.org
Background Double positive (DP) CD4CD8 Tαβ cells have been reported in normal
individuals as well as in different pathological conditions including inflammatory diseases …
individuals as well as in different pathological conditions including inflammatory diseases …
Cytolytic T lymphocyte recognition of the immunodominant HLA-A* 0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
P Romero, N Gervois, J Schneider… - … (Baltimore, Md.: 1950 …, 1997 - journals.aai.org
Abstract The Melan-A/MART-1 gene product is frequently recognized by tumor-specific HLA-
A2-restricted CTL. An immunodominant nonapeptide has been localized to the region …
A2-restricted CTL. An immunodominant nonapeptide has been localized to the region …
[HTML][HTML] Serum soluble HLA-E in melanoma: a new potential immune-related marker in cancer
…, K Bernardeau, A Khammari, B Dreno, N Gervois - PLoS …, 2011 - journals.plos.org
Background Tumor-derived soluble factors, including soluble HLA molecules, can contribute
to cancer immune escape and therefore impact on clinical course of malignant diseases. We …
to cancer immune escape and therefore impact on clinical course of malignant diseases. We …
[HTML][HTML] The inhibitory receptor CD94/NKG2A on CD8+ tumor-infiltrating lymphocytes in colorectal cancer: a promising new druggable immune checkpoint in the …
…, F Dumont, JF Mosnier, C Toquet, A Jarry, N Gervois… - Modern Pathology, 2020 - Elsevier
We previously demonstrated that HLA-E/β2m overexpression by tumor cells in colorectal
cancers is associated with an unfavorable prognosis. However, the expression of its specific …
cancers is associated with an unfavorable prognosis. However, the expression of its specific …